CGEN

This article first appeared on GuruFocus. Cash Balance: Approximately $134.9 million as of March 31, 2026. Revenue: Approximately $2.2 million for Q1 2026, compared to $2.3 million in Q1 2025. R&D Expenses: Approximately $6.9 million for Q1 2026, up from $5.8 million in Q1 2025. G&A Expenses: Approximately $2.3 million for Q1 2026, compared to $2.4 million in Q1 2025. Net Loss: Approximately $7.7 million or $0.08 per share for Q1 2026, compared to $7.2 million or $0.08 per share in Q1 2025. Cash Runway: Expected to fund operations into 2029. Warning! GuruFocus has detected 6 Warning Signs with CGEN. Is CGEN fairly valued? Test your thesis with our free DCF calculator. Release Date: May 18, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Compugen Ltd (NASDAQ:CGEN) is making significant progress with its fully owned clinical program, COM701, which has shown promising results in ovarian cancer treatment. The company has initiated the MAIA-ovarian adaptive platform trial to test COM701 as a maintenance therapy, with active patient enrollment across the United States, Israel, and France. Compugen Ltd (NASDAQ:CGEN) has a solid financial position with a cash runway expected to last into 2029, providing stability and flexibility for future developments. Partnership with AstraZeneca is progressing well, with multiple abstracts presented at the AACR Annual Meeting, reinforcing confidence in the rilvegostomig program. The Unigen discovery engine continues to be a valuable asset, having already discovered targets for COM701, COM902, and GS-0321, and is expected to identify more innovative programs. Revenues for the first quarter of 2026 were slightly lower than the comparable period in 2025, indicating potential challenges in revenue growth. Research and development expenses have increased, primarily due to higher clinical expenses related to the MAIA-ovarian trial and drug supply costs. The net loss for the first quarter of 2026 increased compared to the same period in 2025, reflecting ongoing financial challenges. The MAIA-ovarian trial is exploratory, and the full magnitude of benefit from COM701 is still uncertain, with benchmarks for control arm PFS ranging widely. There is no specific timeline or guidelines for disclosing future development candidates from the Unigen platform, which may lead to uncertainty...

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the company’s first-quarter earnings call, President and Chief Executive Officer Dr. Eran Ophir said 2026 is “shaping up to be a significant year” for Compugen as it advances COM701, its wholly owned antibody targeting PVRIG, and monitors progress on partnered assets with AstraZeneca and Gilead. → 3 Crucial Aerospace Component Makers That Analysts Love Compugen’s lead wholly owned clinical program, COM701, is being evaluated in the MAIA-ovarian adaptive platform trial as maintenance monotherapy compared with placebo in patients with relapsed platinum-sensitive ovarian cancer who responded to their most recent line of chemotherapy. Ophir said the company initiated the study based on prior data presented at ESMO, where pooled clinical data showed COM701, as monotherapy and in combinations, was well-tolerated and produced “consistent, durable responses” in heavily pretreated patients with platinum-resistant ovarian cancer. → 3 Stocks to Own If Gas Prices Keep Rising The company is now testing COM701 in an earlier ovarian cancer setting, with the rationale that patients may have lower tumor burden and a less compromised immune system, potentially improving the likelihood of benefit from COM701’s mechanism of action. Ophir said all clinical sites are open and enrolling across the United States, Israel and France. He said that gives the company confidence in its ability to complete enrollment on schedule for interim median progression-free survival data in the first quarter of 2027. → Peloton Stock Gives Back Gains After Upbeat Earnings Report Chief Medical Officer Dr. Michelle Mahler said during the question-and-answer session that Compugen is not currently commenting on specific enrollment numbers, but remains “on track” for the planned interim analysis. She said the study is stratified by second-line versus third-line treatment, not by PD-L1 status. Ophir added that prior clinical signals with COM701 have been seen in both PD-L1-positive and PD-L1-negative patients, saying PD-L1 stratification may not be the critical factor for the PVRIG-targeting approach. Mahler said t...

Compugen Ltd. (NASDAQ:CGEN) shares jumped more than 18% in premarket trading on Monday after the biotechnology company reported first-quarter revenue ahead of analyst expectations, despite posting a slightly wider-than-expected quarterly loss. The clinical-stage cancer immunotherapy company reported a quarterly loss of $0.08 per share for the period ended March 31, missing analyst estimates that had projected a loss of $0.07 per share. Revenue came in at $2.2 million, exceeding consensus expectations of $1.63 million. However, quarterly revenue was down 4% compared with $2.3 million reported in the first quarter of 2025. Compugen said revenue during the quarter reflected recognition of portions of both the upfront payment and the IND milestone payment tied to its licensing agreement with Gilead. Despite the earnings miss, investors appeared encouraged by stronger-than-expected revenue and continued advancement across the company’s clinical development programs. Compugen said enrollment in its COM701 MAIA-ovarian study is continuing across all participating clinical sites in the United States, Israel and France. The company remains on schedule to conduct an interim analysis during the first quarter of 2027. “Q1 2026 reflects continued execution across all of our programs in line with our strategic priorities,” said Eran Ophir, president and chief executive of Compugen. “With enrollment progressing across all COM701 MAIA-ovarian trial sites, we remain on track for having the median progression-free survival at the interim analysis by Q1 2027, a key potential inflection point for COM701 as a maintenance therapy in a patient population with significant unmet medical need and no current standard of care.” Research and development expenses increased to $6.9 million from $5.8 million a year earlier, primarily driven by higher clinical trial spending related to the MAIA-ovarian program and increased drug supply costs. General and administrative expenses edged slightly lower to $2.3 million from $2.4 million. Compugen reported total cash, cash equivalents, short-term bank deposits and marketable securities of approximately $134.9 million as of March 31, 2026. The company said its current financial resources are expected to support operations through 2029 based on existing development plans. Compugen also noted that partner AstraZeneca is continuing development of ril...

HOLON, Israel (AP) — HOLON, Israel (AP) — Compugen Ltd. (CGEN) on Monday reported a loss of $7.7 million in its first quarter. The Holon, Israel-based company said it had a loss of 8 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 7 cents per share. The drug developer posted revenue of $2.2 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CGEN at https://www.zacks.com/ap/CGEN

COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027 Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026 Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned Solid financial position with cash runway expected to fund operations into 2029 HOLON, Israel, May 18, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today reported financial results for the first quarter of 2026 and provided a corporate update. "Q1 2026 reflects continued execution across all of our programs in line with our strategic priorities," said Eran Ophir, Ph.D., President and CEO of Compugen. "With enrollment progressing across all COM701 MAIA-ovarian trial sites, we remain on track for having the median progression-free survival at the interim analysis by Q1 2027, a key potential inflection point for COM701 as a maintenance therapy in a patient population with significant unmet medical need and no current standard of care." Dr. Ophir continued, "Our partner AstraZeneca continues to broadly advance rilvegostomig. Data presented by AstraZeneca at AACR 2026 reinforces our confidence in its differentiated bispecific design and potential as an immuno-oncology backbone across multiple tumor types, as AstraZeneca progresses rilvegostomig across 11 Phase 3 trials. In addition, we continue to advance the Gilead-partnered GS-0321 Phase 1 trial." Dr. Ophir concluded, "Our solid financial position with cash runway expected into 2029, based on our current plans, enables us to advance our differentiated immuno-oncology pipeline and leverage our AI/ML powered computational discovery platform Unigen™, to discover novel ways to activate the immune system against cancer. I remain encouraged by the progress of our fully owned programs, strengthened by validating partnerships with AstraZeneca and Gilead, which together offer approximately $1 billion in potential milestones plus royalties." First Quarter 2026 Financial Highlights Cash: As of Mar...

Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +157.14%. A quarter ago, it was expected that this company would post earnings of $0.03 per share when it actually produced a loss of $0.11, delivering a surprise of -466.67%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Adherex Technologies, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $15.11 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 8.36%. This compares to year-ago revenues of $8.75 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Adherex Technologies shares have lost about 12.1% since the beginning of the year versus the S&P 500's gain of 8.8%. While Adherex Technologies has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Adherex Technologies was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near f...

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -18.96%. A quarter ago, it was expected that this rare disease biopharmaceutical would post earnings of $0.25 per share when it actually produced earnings of $0.46, delivering a surprise of +84%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. BioMarin, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $766.21 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.50%. This compares to year-ago revenues of $745.15 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. BioMarin shares have lost about 9% since the beginning of the year versus the S&P 500's gain of 5.6%. While BioMarin has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for BioMarin was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of t...

HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its first quarter 2026 financial results on Monday, May 18, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following the live webcast, a replay will be available on the Company's website. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Currently, the only clinical trial we sponsor and are conducting is a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between us and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that we sponsor and are conducting. In addition, Compugen's has an early-stage immuno-oncology pipeline consists of research pr...

This article first appeared on GuruFocus. Cash Balance: $145.6 million as of December 31, 2025. Revenue (Q4 2025): $67.3 million. Revenue (Full Year 2025): $72.8 million. R&D Expenses (Q4 2025): $5.5 million. R&D Expenses (Full Year 2025): $22.8 million. G&A Expenses (Q4 2025): $2.1 million. G&A Expenses (Full Year 2025): $8.9 million. Net Profit (Q4 2025): $56.8 million or $0.60 per share. Net Profit (Full Year 2025): $35.3 million or $0.38 per share. Cash Runway: Expected to fund operations into 2029. Warning! GuruFocus has detected 5 Warning Signs with UUUU. Is CGEN fairly valued? Test your thesis with our free DCF calculator. Release Date: March 02, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Compugen Ltd (NASDAQ:CGEN) extended its cash runway into 2029 through a non-dilutive transaction with AstraZeneca, securing $65 million in upfront capital. The company initiated new clinical trials for its potential first-in-class anti-PVRIG COM701 and anti-IL-18 binding protein antibody GS-0321. Compugen Ltd (NASDAQ:CGEN) presented promising clinical updates at ESMO and SITC conferences for COM701 and GS-0321, respectively. The company has a strong financial outlook with a cash balance of approximately $145.6 million as of December 31, 2025. Compugen Ltd (NASDAQ:CGEN) reported a significant increase in revenues for 2025, totaling approximately $72.8 million, compared to $27.9 million in 2024. The interim analysis for the MAIA-ovarian trial has been delayed to Q1 2027, indicating potential challenges in trial progression. R&D expenses decreased slightly in 2025, which may suggest reduced investment in certain areas of research. The company's net profit for 2025 was largely influenced by the upfront payment from AstraZeneca, raising concerns about sustainable revenue sources. There is uncertainty regarding the timeline and requirements for the path to registration for COM701, as it depends on the totality of the data. The company is reliant on partnerships with AstraZeneca and Gilead for milestone payments, which introduces dependency on external entities for financial milestones. Q: Can you help us level set on what to expect in the 1Q '27 update with COM701 in terms of what we expect to see in that update? And then the follow-up to that is, can you help us understand the timeline and what is required for...

Extended cash runway into 2029 through a $65,000,000 non-dilutive royalty monetization deal with AstraZeneca, securing long-term operational stability without equity dilution. Maintained significant long-term upside in rilvegostomig by retaining the majority of royalty interests and increasing total potential milestones to $195,000,000. Attributed confidence in the TIGIT-based asset rilvegostomig to its differentiated bispecific format with reduced Fc functionality, which aims to avoid immune cell depletion seen in competing programs. Transitioned leadership to a structure combining operational focus under a new CEO with strategic continuity provided by the former CEO moving to Executive Chair. Focused clinical strategy for COM701 on earlier-line maintenance therapy in platinum-sensitive ovarian cancer, targeting a setting with no current standard of care. Leveraged the proprietary Unicigen AI/ML discovery engine to maintain a steady pipeline of novel targets, including the partnered GS-0321 program with Gilead. Validated the therapeutic approach for COM701 through pooled Phase I data showing durable responses in patients without liver metastasis, suggesting higher efficacy in lower disease burden environments. On track for a critical interim analysis of the MAIA ovarian adaptive trial in Q1 2027, which could establish a monotherapy path-to-registration. Anticipate continued expansion of AstraZeneca's Phase III program for rilvegostomig, which now includes 10 active trials and a potential 11th trial in gastric cancer. Plan to advance the Phase I dose-escalation and expansion trial for GS-0321 in collaboration with Gilead, focusing on its unique IL-18 binding protein mechanism. Expect to utilize the 2029 cash runway to reach multiple internal and partnered clinical catalysts while investing in the early-stage computational discovery pipeline. Assume BLA acceptance for rilvegostomig as the next major financial trigger, which would result in a $25,000,000 milestone payment. Reported a significant shift to net profit of $35,300,000 for 2025, primarily driven by the $65,000,000 upfront payment from the AstraZeneca transaction. Reduced R&D expenses to $22,800,000 in 2025 as the company wound down older trials to pivot resources toward the MAIA ovarian study. Confirmed all 28 clinical sites for the MAIA trial are now open across the U.S., Israel, and France after p...

Compugen (CGEN) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +1,053.85%. A quarter ago, it was expected that this drug developer would post a loss of $0.09 per share when it actually produced a loss of $0.07, delivering a surprise of +22.22%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Compugen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $67.33 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 276.79%. This compares to year-ago revenues of $1.47 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Compugen shares have added about 18.3% since the beginning of the year versus the S&P 500's gain of 0.5%. While Compugen has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Compugen was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy...